EIK1001-005: EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Sponsor: Eikon Therapeutics
Full Title
EIK1001-005: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer
Study Treatment
Toll-Like Receptor 7 and 8 co-agonist, EIK1001 given in combination with chemotherapy and pembrolizumab
Eligibility/Info
- Stage IV squamous or non-squamous non-small cell lung cancer
- No history of systemic therapy in the advanced/metastatic setting
- No actionable mutation
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
